Three guided third-quarter obesity milestones are still unannounced with weeks to go

As of September 8, 2026, three separate company promises about obesity drug trials due this quarter had not been kept, with only 22 days left before the quarter closes.^[1] Structure Therapeutics had said it would start Phase 3 testing of its oral pill aleniglipron sometime in the third quarter. Viking Therapeutics had guided to a topline result from its VANQUISH-2 study, which enrolls people with type 2 diabetes. And Zealand Pharma, working with its partner Roche, had said it would begin registrational Phase 3 trials of petrelintide, an amylin-based drug, tested alone. None of the three had happened yet as of the September 8 update.^[1]

One company in this group of smaller drugmakers did hit its target. Ascletis Pharma dosed the first patient in its global Phase 3 program for ASC30, a once-daily oral pill, on August 30, 2026.^[2] That program, called AURORA-1 and AURORA-2, will enroll about 4,600 people at sites in the United States, Europe, and Canada. It tests 20, 40, and 60 milligram doses over 72 weeks, with one study for people without type 2 diabetes and one for people with it.^[2] Ascletis has guided to a topline result in the third quarter of 2028, an FDA filing by the end of that year, and a European filing in early 2029.^[2] The company itself describes ASC30 as a candidate to become the second oral small-molecule GLP-1 drug in the U.S. and Europe—meaning it would follow Eli Lilly's orforglipron, branded Foundayo, rather than compete for a first-mover spot.^[2]

The unmet milestones matter because each one marks a different kind of drug. Aleniglipron is an oral small molecule that showed about 16.3% placebo-adjusted weight loss over 44 weeks in earlier testing, and Structure Therapeutics has said its Phase 3 start would follow positive feedback from an end-of-Phase-2 meeting with the FDA.^[1] Viking's VK2735 platform, which includes both an injectable and a pill form, has shown up to 14.7% weight loss in short 13-week studies; the company's real make-or-break moment is a separate, later readout called VANQUISH-1, expected in late 2027.^[1] Petrelintide, Zealand's amylin drug, showed about 10.7% weight loss over 42 weeks with tolerability described as close to placebo, and Roche has backed it with a deal worth up to $5.3 billion.^[1]

Why it matters for patients

None of these delays, by themselves, mean a drug has failed. Missing a guided quarter is common in drug development and does not necessarily change a medicine's chances of eventually reaching pharmacies. But the timing does affect how soon patients might have new choices beyond the currently approved options—semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), and orforglipron (Foundayo).^[1] Structure Therapeutics has said its own drug would not reach the market until around 2029 even on schedule, placing it behind the current leaders regardless.^[1] Viking's decisive data will not arrive until late 2027 no matter what happens with VANQUISH-2 this quarter.^[1] For patients weighing today's decisions, these are pipeline signals about the future field, not the status of any drug now available.

What happens next

With 22 days left in the third quarter as of September 8, watchers of the field are looking for confirmation, or a slip in guidance, from Structure Therapeutics on its Phase 3 start, from Viking on VANQUISH-2 topline data, and from Zealand and Roche on the start of registrational petrelintide trials.^[1] Ascletis's next disclosed milestone is a topline readout guided for the third quarter of 2028.^[2]